Marketed therapeutic antibodies compendium
Open Access
- 1 May 2012
- journal article
- Published by Taylor & Francis Ltd in mAbs
- Vol. 4 (3), 413-415
- https://doi.org/10.4161/mabs.19931
Abstract
Therapeutic monoclonal antibodies (mAbs) are currently being approved for marketing in Europe and the United States, as well as other countries, on a regular basis. As more mAbs become available to physicians and patients, keeping track of the number, types, production cell lines, antigenic targets, and dates and locations of approvals has become challenging. Data are presented here for 34 mAbs that were approved in either Europe or the United States (US) as of March 2012, and nimotuzumab, which is marketed outside Europe and the US. Of the 34 mAbs, 28 (abciximab, rituximab, basiliximab, palivizumab, infliximab, trastuzumab, alemtuzumab, adalimumab, tositumomab-I131, cetuximab, ibrituximab tiuxetan, omalizumab, bevacizumab, natalizumab, ranibizumab, panitumumab, eculizumab, certolizumab pegol, golimumab, canakinumab, catumaxomab, ustekinumab, tocilizumab, ofatumumab, denosumab, belimumab, ipilimumab, brentuximab) are currently marketed in Europe or the US. Data for six therapeutic mAbs (muromonab-CD3, nebacumab, edrecolomab, daclizumab, gemtuzumab ozogamicin, efalizumab) that were approved but have been withdrawn or discontinued from marketing in Europe or the US are also included.Keywords
This publication has 9 references indexed in Scilit:
- The birth pangs of monoclonal antibody therapeuticsmAbs, 2012
- Which are the antibodies to watch in 2012?mAbs, 2012
- Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell LymphomaJournal of Clinical Oncology, 2010
- Antibody immunosuppressive therapy in solid-organ transplantmAbs, 2010
- Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originmAbs, 2009
- Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised studyThe Lancet, 2002
- Delaying approval of a critical drug: Safety, efficacy, economics, compassionJournal of Medical Humanities, 1994
- Expression of spleen cell immunoglobulin phenotype in hybrids with myeloma cell linesSomatic Cell and Molecular Genetics, 1981
- A better cell line for making hybridomas secreting specific antibodiesNature, 1978